Hepatocellular carcinoma and the risk of de novo malignancies after liver transplantation - a multicenter cohort study.
de novo malignancies
liver transplant
post-transplant neoplastic screening
post-transplant survival
solid tumors
Journal
Transplant international : official journal of the European Society for Organ Transplantation
ISSN: 1432-2277
Titre abrégé: Transpl Int
Pays: Switzerland
ID NLM: 8908516
Informations de publication
Date de publication:
04 2021
04 2021
Historique:
revised:
22
09
2020
received:
01
09
2020
accepted:
20
01
2021
pubmed:
26
1
2021
medline:
29
6
2021
entrez:
25
1
2021
Statut:
ppublish
Résumé
Patients with hepatocellular carcinoma (HCC) are at high risk of second primary malignancies. As HCC has become the leading indication of liver transplant (LT), the aim of this study was to investigate whether the presence of HCC before LT could influence the onset of de novo malignancies (DNM). A cohort study was conducted on 2653 LT recipients. Hazard ratios (HR) of DNM development for patients transplanted for HCC (HCC patients) were compared with those of patients without any previous malignancy (non-HCC patients). All models were adjusted for sex, age, calendar year at transplant, and liver disease etiology. Throughout 17 903 person-years, 6.6% of HCC patients and 7.4% of non-HCC patients developed DNM (202 cases). The median time from LT to first DNM diagnosis was shorter for solid tumors in HCC patients (2.7 vs 4.5 years for HCC and non-HCC patients, respectively, P < 0.01). HCC patients were at a higher risk of bladder cancer and skin melanoma. There were no differences in cumulative DNM-specific mortality by HCC status. This study suggests that primary HCC could be a risk factor for DNM in LT recipients, allowing for risk stratification and screening individualization.
Types de publication
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
743-753Subventions
Organisme : Associazione Italiana per la Ricerca sul Cancro
Informations de copyright
© 2021 Steunstichting ESOT. Published by John Wiley & Sons Ltd.
Références
Baccarani U, Adani GL, Serraino D, et al. De novo tumors are a major cause of late mortality after orthotopic liver transplantation. Transplant Proc 2009; 41: 1303.
Baccarani U, Piselli P, Serraino D, et al. Comparison of de novo tumours after liver transplantation with incidence rates from Italian cancer registries. Dig Liver Dis 2010; 42: 55.
Chapman JR, Webster AC, Wong G. Cancer in the transplant recipient. Cold Spring Harb Perspect Med 2013; 3: a015677.
Daniel KE, Eickhoff J, Lucey MR. Why do patients die after a liver transplantation? Clin Transplant 2017; 31: e12906.
Taborelli M, Piselli P, Ettorre GM, et al. Risk of virus and non-virus related malignancies following immunosuppression in a cohort of liver transplant recipients. Italy, 1985-2014. Int J Cancer 2018; 143: 1588.
Toniutto P, Zanetto A, Ferrarese A, Burra P. Current challenges and future directions for liver transplantation. Liver Int 2017; 37: 317.
Zhou J, Hu Z, Zhang Q, et al. Spectrum of de novo cancers and predictors in liver transplantation: analysis of the scientific registry of transplant recipients database. PLoS One 2016; 11: e0155179.
Seree O, Altieri M, Guillaume E, et al. Longterm risk of solid organ de novo malignancies after liver transplantation: a French national study on 11,226 patients. Liver Transpl 2018; 24: 1425.
Finkenstedt A, Graziadei IW, Oberaigner W, et al. Extensive surveillance promotes early diagnosis and improved survival of de novo malignancies in liver transplant recipients. Am J Transplant 2009; 9: 2355.
Taborelli M, Piselli P, Ettorre GM, et al. Survival after the diagnosis of de novo malignancy in liver transplant recipients. Int J Cancer 2019; 144: 232.
Chak E, Saab S. Risk factors and incidence of de novo malignancy in liver transplant recipients: a systematic review. Liver Int 2010; 30: 1247.
Piselli P, Burra P, Lauro A, et al. Head and neck and esophageal cancers after liver transplant: results from a multicenter cohort study. Italy, 1997-2010. Transpl Int 2015; 28: 841.
Watt KD, Pedersen RA, Kremers WK, Heimbach JK, Sanchez W, Gores GJ. Long-term probability of and mortality from de novo malignancy after liver transplantation. Gastroenterology 2009; 137: 2010.
Burra P, Shalaby S, Zanetto A. Long-term care of transplant recipients: de novo neoplasms after liver transplantation. Curr Opin Organ Transplant 2018; 23: 187.
Burra P, Rodriguez-Castro KI. Neoplastic disease after liver transplantation: Focus on de novo neoplasms. World J Gastroenterol 2015; 21: 8753.
Carenco C, Faure S, Herrero A, et al. Incidence of solid organ cancers after liver transplantation: comparison with regional cancer incidence rates and risk factors. Liver Int 2015; 35: 1748.
Yang JD, Larson JJ, Watt KD, et al. Hepatocellular carcinoma is the most common indication for liver transplantation and placement on the waitlist in the United States. Clin Gastroenterol Hepatol 2017; 15: 767.
Ghimire KB, Shah BK. Second primary malignancies in adult acute lymphoblastic leukemia: a US population-based study. Blood 2014; 124: 2000.
Nzeako UC, Goodman ZD, Ishak KG. Association of hepatocellular carcinoma in North American patients with extrahepatic primary malignancies. Cancer 1994; 74: 2765.
Shah BK, Budhathoki N. Second primary malignancy in anal carcinoma-A US population-based study. Anticancer Res 2015; 35: 4131.
Fernandez-Ruiz M, Guerra-Vales JM, Castelbon-Fernandez FJ, Llenas-Garcia J, Caurcel-Diaz L, Colina-Ruizdelgado F. Multiple primary malignancies in Spanish patients with hepatocellular carcinoma: analysis of a hospital-based tumor registry. J Gastroenterol Hepatol 2009; 24: 1424.
Wong LL, Lurie F, Takanishi DM Jr. Other primary neoplasms in patients with hepatocellular cancer: prognostic implications? Hawaii Med J 2007;66:204, 6-8.
Takayasu K, Kasugai H, Ikeya S, et al. A clinical and radiologic study of primary liver cancer associated with extrahepatic primary cancer. Cancer 1992; 69: 45.
Shimada M, Takenaka K, Fujiwara Y, et al. Characteristics of hepatocellular carcinoma associated with extrahepatic primary malignancies in southern Japan. Am J Gastroenterol 1996; 91: 754.
Wu WC, Chen YT, Hwang CY, et al. Second primary cancers in patients with hepatocellular carcinoma: a nationwide cohort study in Taiwan. Liver Int 2013; 33: 616.
Bruno G, Andreozzi P, Graf U, Santangelo G. Hepatitis C virus: a high risk factor for a second primary malignancy besides hepatocellular carcinoma. Fact or fiction? Clin Ter 1999; 150: 413.
Di Stasi M, Sbolli G, Fornari F, et al. Extrahepatic primary malignant neoplasms associated with hepatocellular carcinoma: high occurrence of B cell tumors. Oncology 1994; 51: 459.
Onitsuka A, Hirose H, Ozeki Y, Hino A, Senga S, Iida T. Clinical study on hepatocellular carcinoma with extrahepatic malignancies. Int Surg 1995; 80: 128.
Kanematsu M, Imaeda T, Yamawaki Y, et al. Hepatocellular carcinoma with extrahepatic primary neoplasms. Gastrointest Radiol 1992; 17: 53.
Heo J, Noh OK, Oh YT, Chun M, Kim L. Second primary cancer after liver transplantation in hepatocellular carcinoma: a nationwide population-based study. Hepatol Int 2017;11:523.
Oweira H, Schmidt J, Helbling D, et al. Impact of liver transplantation on the risk of second malignant tumors among hepatocellular carcinoma patients. Expert Rev Gastroenterol Hepatol 2017; 11: 865.
Park GC, Hwang S, Ahn CS, et al. Pretransplant hepatic malignancy increases risk of de novo malignancy after liver transplantation. J Korean Med Sci 2020; 35: e69.
Kanwal F, Kramer JR, Mapakshi S, et al. Risk of hepatocellular cancer in patients with non-alcoholic fatty liver disease. Gastroenterology 2018; 155: 1828.
Herrero JI, Espana A, D'Avola D, et al. Subsequent nonmelanoma skin cancer after liver transplantation. Transplant Proc 2012; 44: 1568.
Modaresi Esfeh J, Hanouneh IA, Dalal D, et al. The incidence and risk factors of de novo skin cancer in the liver transplant recipients. Int J Organ Transplant Med 2012; 3: 157.
Xiol X, Guardiola J, Menendez S, et al. Risk factors for development of de novo neoplasia after liver transplantation. Liver Transpl 2001; 7: 971.
Sanaei AK, Aliakbarian M, Kazemi K, et al. De novo malignancy after liver transplant. Exp Clin Transplant 2015; 13: 163.
Jain AB, Yee LD, Nalesnik MA, et al. Comparative incidence of de novo nonlymphoid malignancies after liver transplantation under tacrolimus using surveillance epidemiologic end result data. Transplantation 1998; 66: 1193.
Saigal S, Norris S, Muiesan P, Rela M, Heaton N, O'Grady J. Evidence of differential risk for posttransplantation malignancy based on pretransplantation cause in patients undergoing liver transplantation. Liver Transpl 2002; 8: 482.
Adami J, Gabel H, Lindelof B, et al. Cancer risk following organ transplantation: a nationwide cohort study in Sweden. Br J Cancer 2003; 89: 1221.
Collett D, Mumford L, Banner NR, Neuberger J, Watson C. Comparison of the incidence of malignancy in recipients of different types of organ: a UK Registry audit. Am J Transplant 2010; 10: 1889.
Engels EA, Pfeiffer RM, Fraumeni JF Jr, et al. Spectrum of cancer risk among US solid organ transplant recipients. JAMA 2011; 306: 1891.
Maggi U, Consonni D, Manini MA, et al. Early and late de novo tumors after liver transplantation in adults: the late onset of bladder tumors in men. PLoS One 2013; 8: e65238.
Katoh M. Multilayered prevention and treatment of chronic inflammation, organ fibrosis and cancer associated with canonical WNT/betacatenin signaling activation (Review). Int J Mol Med 2018; 42: 713.
Guichard C, Amaddeo G, Imbeaud S, et al. Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. Nat Genet 2012; 44: 694.
Aguiar D, Martinez-Urbistondo D, D'Avola D, et al. Conversion from calcineurin inhibitor-based immunosuppression to mycophenolate mofetil in monotherapy reduces risk of de novo malignancies after liver transplantation. Ann Transplant 2017; 22: 141.